Abstract

BackgroundMost of the non-B HIV-1 subtypes are predominant in Sub-Saharan Africa and India although they have been found worldwide. In the last decade, immigration from these areas has increased considerably in Spain. The objective of this study was to evaluate the prevalence of non-B subtypes circulating in a cohort of HIV-1-infected immigrants in Seville, Southern Spain and to identify drug resistance-associated mutations.MethodsComplete protease and first 220 codons of the reverse transcriptase coding regions were amplified and sequenced by population sequencing. HIV-1 subtypes were determined using Stanford University Drug Resistance Database, and phylogenetic analysis was performed comparing multiple reported sequences. Drug resistance mutations were defined according to the International AIDS Society-USA.ResultsFrom 2000 to 2010 a total of 1,089 newly diagnosed HIV-1-infected patients were enrolled in our cohort. Of these, 121 were immigrants, of which 98 had ethical approval and informed consent to include in our study. Twenty-nine immigrants (29/98, 29.6%) were infected with non-B subtypes, of which 15/29 (51.7%) were CRF02-AG, mostly from Sub-Saharan Africa, and 2/29 (6.9%) were CRF01-AE from Eastern Europe. A, C, F, J and G subtypes from Eastern Europe, Central-South America and Sub-Saharan Africa were also present. Some others harboured recombinant forms CRF02-AG/CRF01-AE, CRF2-AG/G and F/B, B/C, and K/G, in PR and RT-coding regions. Patients infected with non-B subtypes showed a high frequency of minor protease inhibitor resistance mutations, M36I, L63P, and K20R/I. Only one patient, CRF02_AG, showed major resistance mutation L90M. Major RT inhibitor resistance mutations K70R and A98G were present in one patient with subtype G, L100I in one patient with CRF01_AE, and K103N in another patient with CRF01_AE. Three patients had other mutations such as V118I, E138A and V90I.ConclusionsThe circulation of non-B subtypes has significantly increased in Southern Spain during the last decade, with 29.6% prevalence, in association with demographic changes among immigrants. This could be an issue in the treatment and management of these patients. Resistance mutations have been detected in these patients with a prevalence of 7% among treatment-naïve patients compared with the 21% detected among patients under HAART or during treatment interruption.

Highlights

  • Most of the non-B Human immunodeficiency virus type 1 (HIV-1) subtypes are predominant in Sub-Saharan Africa and India they have been found worldwide

  • The study population was grouped into seven categories according to their home countries: Central-South America (Argentina, Peru, Brazil, Colombia, Cuba, Bolivia, Ecuador, El Salvador, Guatemala, Panama, Paraguay, Dominican Republic and Venezuela), Western Europe (France, Italy, Portugal, Belgium, Germany and Ireland), Sub-Saharan Africa (Nigeria, Cameroon, Angola, Uganda, Sierra Leone, Guinea, Cote d’Ivoire), Northern Africa (Morocco), Eastern Europe (Romania, Ukraine and Russia), Table 1 Characteristics of the 98 HIV-1-infected immigrant individuals studied

  • This study evaluates the prevalence of HIV-1 subtypes and PR and reverse transcriptase (RT) drug resistance mutations among HIV1-infected immigrants living in Southern Spain

Read more

Summary

Introduction

Most of the non-B HIV-1 subtypes are predominant in Sub-Saharan Africa and India they have been found worldwide. Subtype B is predominant in North America and Western Europe, including Spain, is responsible for only 10% of global infections [1]. Non-B HIV-1 subtypes and its recombinants, such as subtype C, A, CRF01_AE or CRF02_AG, are prevalent in Sub-Saharan Africa, Asia and Eastern Europe [2]. These subtypes cause up to 90% of the 36 million estimated infections, playing an important role in the HIV-1 pandemic [3,4]. Human migration produced in the last decade has contributed to the current spread of non-B subtypes in developed countries [5,6,7]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.